Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,950

Document Document Title
WO/2018/106916A1
This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1, 2,3-de]quinoxalines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this inve...  
WO/2018/099271A1
The prevent invention provides a method for preparing deuterated chemicals, and deuterated chemicals. The method comprises the step of: making halides undergo a deuteration reaction with a deuterium source under the catalytic action of a...  
WO/2018/095386A1
Disclosed in the present invention are a fused ring compound and applications thereof in organic electronic components, particularly in organic electroluminescent diodes. Also disclosed in the present invention are an organic electronic ...  
WO/2018/094116A1
Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsat...  
WO/2018/081858A1
The present invention relates to new desferrioxamine B analogues that are useful for iron-chelation therapy, to their preparation including intermediates, and to compositions including the compounds. The present invention also relates to...  
WO/2018/080591A1
Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator. The method comprises administering to the subject Compoind (I) or pharmaceutically acce...  
WO/2018/072300A1
Disclosed is a method for preparing a deuterated imidazole diketone compound, comprising the following steps: (1) using a compound of formula (I) and a compound of formula (II) as raw materials to obtain a compound of formula (III) by me...  
WO/2018/067771A1
Tin(IV)-117m is reduced by an acidic antimony solution to tin(II)-117m. A chelant is added to the solution of tin(II)-117m, and the pH is raised, forming tin(II)-117m chelant complex. The chelant is a bifunctional chelant, preferably att...  
WO/2018/064092A1
Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors...  
WO/2018/046662A1
The present invention relates to a positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F] -labelled lactate derivative. The invention also provides a process for the radiosynthesis of the...  
WO/2018/037097A1
The present invention concerns a method for preparing a microorganism hydrolysate of which at least one amino acid and/or one amino acid precursor is labelled, comprising a step of obtaining a microorganism hydrolysate in solution in whi...  
WO/2018/035610A1
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).  
WO/2018/028541A1
Provided is a substituted quinoline compound and a pharmaceutical composition and a use thereof.The quinoline compound is a compound as shown in formula (I), or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate t...  
WO/2018/024642A1
The invention relates to 9H-pyrrolo-dipyridine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection ...  
WO/2018/023116A1
Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify β-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable ...  
WO/2018/022125A1
Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: [Formula sh...  
WO/2018/022603A1
Described herein are novel methods for the synthesis of radiolabeling synthons such as [18F]fluoronicotinic acid-2,3,5,6-tetrafluorophenyl ester, and also methods of labeling a protein or peptide comprising a free amine group. A novel c-...  
WO/2018/023115A1
Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify β-N-methylamino-L-alanine (BMAA) in the Cu/Zn Superoxide Dismutase 1 (SOD1) prote...  
WO/2018/015307A1
The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising ...  
WO/2018/015549A1
The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies usin...  
WO/2018/015546A1
The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using...  
WO/2018/008311A1
[Problem] To provide 11C-labelled O6-benzylguanine with which PET images can be obtained, and a production method therefor. [Solution] This 11C-labelled O6-benzylguanine is characterized by being represented by chemical formula (a). The ...  
WO/2018/005625A1
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula (I) or a pharmace...  
WO/2017/210302A1
Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.  
WO/2017/206801A1
Disclosed are a class of diarylsulfide derivatives, a preparation method therefor, and the use thereof as a serotonin transporter-targeted imaging agent, belonging to the field of radiopharmaceutical chemistry. The diarylsulfide derivati...  
WO/2017/202206A1
The present invention discloses a substituted quinoline compound as shown in formula (I), a pharmaceutical composition comprising said compound or a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotopic va...  
WO/2017/191604A3
The invention relates to a process for the preparation of complexes of the 68Ga radioisotope in which the complexation reaction between a chelator- functionalised molecule and 68Ga occurs in the presence of a neutralising agent (preferab...  
WO/2017/181918A1
The present invention discloses a substituted phthalazone, wherein the substituted phthalazone is a compound represented by formula (I). The invention further discloses a pharmaceutical composition comprising the compound, or a crystalli...  
WO/2017/180492A1
A system, and method, for quantitatively mapping of mitochondrial membrane potential of a tissue in a subject is provided. In some aspects, the provided method includes administering to the subject a detectably effective amount of a trac...  
WO/2017/180589A1
The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing...  
WO/2017/157137A1
Provided in the present invention is a new type acyclic nucleoside analogue and a pharmaceutical composition thereof, wherein the new type nucleoside analogue is the compound as shown by formula (I), or a crystal form, a pharmaceutically...  
WO/2017/152677A1
The present invention relates to a cholanic acid compound for preventing or treating FXR-mediated diseases. Specifically, disclosed are a cholanic acid compound represented by formula (I) and a pharmaceutical composition containing the c...  
WO/2017/144639A1
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2017/140183A1
Provided are substituted steroids and a use thereof. In particular, the substituted steroids of the present invention are steroids as shown by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer,...  
WO/2017/133337A1
The present invention provides a substituted benzimidazolone compound and a composition comprising the same. The present invention discloses a substituted benzimidazolone compound represented by formula (I) and a pharmaceutical compositi...  
WO/2017/134098A1
The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising ...  
WO/2017/117070A1
The invention provides novel chemical compounds useful for treating cancer or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.  
WO/2017/103179A1
The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission...  
WO/2017/103182A1
The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emi...  
WO/2017/090354A1
[Problem] To provide an aromatic compound methylation method, in which a reaction substrate that serves as a raw material can be synthesized easily, and which can be employed as a method for producing a [11C]-labeled tracer for PET use. ...  
WO/2017/089492A1
The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and...  
WO/2017/087207A1
The invention provides novel chemical compounds useful for treating various hematologic malignancies and inflammatory and autoimmune diseases or a related disease or disorder thereof, and pharmaceutical composition and methods of prepara...  
WO/2017/076879A1
Radiotracer compositions comprising a radiotracer compound comprising [18F]SO3F-, [18F]PF6 - or [18F]PO2F2 -, methods of synthesising such radiotracer compounds, kits for synthesising such compounds, and the use of such compounds in a di...  
WO/2017/079003A1
The invention provides novel chemical compounds useful for treating various blood cancers, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.  
WO/2017/078928A1
Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subje...  
WO/2017/072200A1
The present invention relates to new and improved methods of synthesizing radiolabelling agents which can be used to label biomolecules for use as radiopharmaceuticals. It further relates to certain novel radiolabelling agents and their ...  
WO/2017/070752A1
The present invention provides certain thiosemicarbazone metal complexes which have advantageous properties in medical imaging. The thiosemicarbazone metal complexes can be safely and easily produced in real time, administered quickly af...  
WO/2017/065899A1
Described are deuterated chlorokynurenines and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulating N-methyl-D-aspartate (NMDA) receptor activity, methods of treating disorders, inclu...  
WO/2017/055859A1
The invention provides a compound of formula (I): (I) or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions co...  
WO/2017/055860A1
The invention provides a compound of formula (I): (I) or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions co...  

Matches 1 - 50 out of 1,950